Abstract: Methods, apparatus, and computer programs are disclosed for context switching. In some embodiments, a method comprises dedicating a first subset of a plurality of vector registers to a first thread of a plurality of threads for thread execution; and responsive to a context switch from the first thread to a second thread, bypassing saving a state of the first subset of the plurality of vector registers; and saving a state of a second subset of the plurality of vector registers, wherein the second subset of the plurality of vector registers is not dedicated to the first thread, and wherein the first and second subsets are mutually exclusive.

Abstract: Systems and methods described provide dynamic and intelligent ways to change the required level of user interaction during use of a monitoring device. The systems and methods generally relate to real time switching between a first or initial mode of user interaction and a second or new mode of user interaction. In some cases, the switching will be automatic and transparent to the user, and in other cases user notification may occur. The mode switching generally affects the user's interaction with the device, and not just internal processing. The mode switching may relate to calibration modes, data transmission modes, control modes, or the like.

Abstract: Aspects of the disclosure relate to fluid injection systems, apparatus, methods, and associated components thereof that include flexible hoses for wellhead sites. In one implementation, a fluid injection system for wellhead sites includes a pump, a pump manifold, and a flexible hose coupled between the pump and the pump manifold. The flexible hose includes a first end coupled to the pump and a second end coupled to the pump manifold. The first end of the flexible hose includes a first end fitting coupled to the pump, and the first end fitting is oriented at an angle relative to a horizontal plane. The second end of the flexible hose includes a second end fitting coupled to the pump manifold, and the second end fitting is oriented vertically and perpendicularly to the horizontal plane.

Abstract: Forming a hardmask layer for reactive ion etching includes depositing a hardmask above an underlayer. The hardmask includes a layer of magnesium oxide having a thickness of up to 10 nm. A resist layer is deposited above the hardmask and developed to form a pattern that exposes portions of the hardmask. The pattern is transferred from the resist layer to the hardmask by rinsing exposed portions of the hardmask with a deionized water solution.

Abstract: Methods and apparatus are disclosed for managing streamed audio communication sessions between user devices (50) configured to send streamed data indicative of received audio contributions from respective participants in a multiple-participant audio communication session via a communications network to one or more other user devices (50) for conversion to audio representations of said received audio contributions for other participants.

Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.

Abstract: Methods and apparatus are disclosed for managing streamed audio communication sessions between user devices (50) configured to send streamed data indicative of received audio contributions from respective participants in a multiple-participant audio communication session via a communications network to one or more other user devices (50) for conversion to audio representations of said received audio contributions for other participants.

Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.

Abstract: To represent the indirect lifecycle binding between the validity of data for a given topic, and the presence of sessions responsible for updating the data associated with that topic, sessions may register a policy referred to herein as a “session will” against specific nodes in the topic tree maintained by a data distribution system server. A session will binds the lifecycle of the topic node to that of the registering session. When a session that is responsible for updating a particular topic is disconnected, the data distribution system server initiates actions in accordance with the session will to determine how to manage updating the topic and the sub-topics in the topic path.

Abstract: To represent the indirect lifecycle binding between the validity of data for a given topic, and the presence of sessions responsible for updating the data associated with that topic, sessions may register a policy referred to herein as a “session will” against specific nodes in the topic tree maintained by a data distribution system server. A session will binds the lifecycle of the topic node to that of the registering session. When a session that is responsible for updating a particular topic is disconnected, the data distribution system server initiates actions in accordance with the session will to determine how to manage updating the topic and the sub-topics in the topic path.

Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.

Abstract: Apparatuses and methods (including methods of using such apparatuses) for de-noising electrocardiograms (ECGs) by manually or automatically adjusting the amount of filtering of an ECG signal. For example, real-time ECG signals may be filtered by combining in a weighted fashion an unfiltered portion of an ECG (or a filtered portion of the same ECG) with the same portion of the ECG that has been filtered. The weighting may be adjusted manually and/or automatically. Also described herein are methods for real-time filtering of ECG signals using a combination of filtering techniques including filtering to correct baseline wander, Savitzky-Golay denoising, and threshold smoothing. Multiple filtering techniques may be combined in a weighed manner to provide signal de-noising.

Abstract: Apparatuses and methods (including methods of using such apparatuses) for de-noising electrocardiograms (ECGs) by manually or automatically adjusting the amount of filtering of an ECG signal. For example, real-time ECG signals may be filtered by combining in a weighted fashion an unfiltered portion of an ECG (or a filtered portion of the same ECG) with the same portion of the ECG that has been filtered. The weighting may be adjusted manually and/or automatically. Also described herein are methods for real-time filtering of ECG signals using a combination of filtering techniques including filtering to correct baseline wander, Savitzky-Golay denoising, and threshold smoothing. Multiple filtering techniques may be combined in a weighed manner to provide signal de-noising.

Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.

Abstract: Apparatuses and methods (including methods of using such apparatuses) for de-noising electrocardiograms (ECGs) by manually or automatically adjusting the amount of filtering of an ECG signal. For example, real-time ECG signals may be filtered by combining in a weighted fashion an unfiltered portion of an ECG (or a filtered portion of the same ECG) with the same portion of the ECG that has been filtered. The weighting may be adjusted manually and/or automatically. Also described herein are methods for real-time filtering of ECG signals using a combination of filtering techniques including filtering to correct baseline wander, Savitzky-Golay denoising, and threshold smoothing. Multiple filtering techniques may be combined in a weighed manner to provide signal de-noising.

Abstract: Apparatuses and methods (including methods of using such apparatuses) for de-noising electrocardiograms (ECGs) by manually or automatically adjusting the amount of filtering of an ECG signal. For example, real-time ECG signals may be filtered by combining in a weighted fashion an unfiltered portion of an ECG (or a filtered portion of the same ECG) with the same portion of the ECG that has been filtered. The weighting may be adjusted manually and/or automatically. Also described herein are methods for real-time filtering of ECG signals using a combination of filtering techniques including filtering to correct baseline wander, Savitzky-Golay denoising, and threshold smoothing. Multiple filtering techniques may be combined in a weighed manner to provide signal de-noising.

Abstract: The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib.

Abstract: Apparatuses and methods (including methods of using such apparatuses) for de-noising electrocardiograms (ECGs) by manually or automatically adjusting the amount of filtering of an ECG signal. For example, real-time ECG signals may be filtered by combining in a weighted fashion an unfiltered portion of an ECG (or a filtered portion of the same ECG) with the same portion of the ECG that has been filtered. The weighting may be adjusted manually and/or automatically. Also described herein are methods for real-time filtering of ECG signals using a combination of filtering techniques including filtering to correct baseline wander, Savitzky-Golay denoising, and threshold smoothing. Multiple filtering techniques may be combined in a weighed manner to provide signal de-noising.

Abstract: A tracheal tube (40) or laryngeal mask has a sealing cuff (41, 2) with a surface covered by a brush-like material (44, 24) provided by closely-packed fibers (25) between 1 mm and 5 mm in length. The brush-like surface (44, 24) may be provided by coating the surface with an adhesive and using an electrostatic charge to draw fibers (25) to adhere to the adhesive.

Abstract: The process for converting a copper sulphide matte to blister copper, is achieved by adding the copper sulphide matte and flux to a suitable agitated slag phase; and injecting, from a discharge tip at the lower end of a top-submerged lance, an oxidizing gas suitable for reacting with the matte to produce blister copper which forms or adds to a continuous blister copper phase below the slag phase. The lance tip is located within the slag phase at a depth enabling the injected gas to agitate the slag phase, and to react with copper sulphide matte dispersed therein, while precluding a substantial proportion of the gas from contacting the continuous blister copper phase.